Abstract
First described in organ transplant recipients in 1968, post-transplant lymphoproliferative disorder (PTLD) remains an often devastating complication of immunosuppression. Similar, if not identical, Epstein-Barr virus (EBV)-associated B lymphoproliferations have since been described in congenital and other acquired immunodeficiency states. Although PTLD is often morphologically indistinguishable from aggressive non-Hodgkin's lymphoma, the pathogenesis, presentation, clinical course, and management options differ significantly from those of classic NHL.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Herpesviridae Infections / epidemiology
-
Herpesvirus 4, Human / growth & development
-
Herpesvirus 4, Human / pathogenicity
-
Humans
-
Immunocompromised Host
-
Immunosuppression Therapy / adverse effects*
-
Immunotherapy
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use
-
Lymphoma, Non-Hodgkin / etiology
-
Lymphoma, Non-Hodgkin / mortality
-
Lymphoma, Non-Hodgkin / pathology
-
Lymphoma, Non-Hodgkin / therapy*
-
Lymphoma, Non-Hodgkin / virology
-
Postoperative Complications / etiology
-
Postoperative Complications / mortality
-
Postoperative Complications / pathology
-
Postoperative Complications / therapy*
-
Postoperative Complications / virology
-
Recombinant Proteins
-
Transplantation / adverse effects*
-
Tumor Virus Infections / epidemiology
-
Virus Activation
Substances
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins